{"title":"L’intelligence artificielle, une révolution en marche pour la pratique officinale","authors":"Sébastien Faure (Professeur des universités)","doi":"10.1016/j.actpha.2025.04.001","DOIUrl":"10.1016/j.actpha.2025.04.001","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 647","pages":"Page 1"},"PeriodicalIF":0.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Évaluez-vous !","authors":"Élisa Derrien (Rédactrice en chef)","doi":"10.1016/j.actpha.2025.04.014","DOIUrl":"10.1016/j.actpha.2025.04.014","url":null,"abstract":"<div><div>Ce QCM vous permet de vérifier les connaissances acquises à la lecture du numéro d’<em>Actualités pharmaceutiques</em>.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 647","pages":"Pages 62-64"},"PeriodicalIF":0.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Manon Malbos (Étudiante en 5e année de pharmacie, filière officine)
{"title":"Méthotrexate, acide folique et prednisone","authors":"Manon Malbos (Étudiante en 5e année de pharmacie, filière officine)","doi":"10.1016/j.actpha.2025.04.003","DOIUrl":"10.1016/j.actpha.2025.04.003","url":null,"abstract":"<div><div>La polyarthrite rhumatoïde est une maladie articulaire inflammatoire auto-immune pour laquelle le pharmacien dispense de nombreuses ordonnances. L’adhésion médicamenteuse des patients qui en sont atteints est un point clé dans la quête d’une rémission clinique. Il est donc nécessaire d’optimiser leur prise en charge à l’officine et de les accompagner au mieux durant leur parcours thérapeutique.</div></div><div><div>Rheumatoid arthritis is an autoimmune inflammatory joint disease for which pharmacists dispense many prescriptions. Adherence to medication is a key factor in patients’ quest for clinical remission. It is therefore essential to optimize their management in the pharmacy, and to provide them with the best possible support throughout their therapeutic journey.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 647","pages":"Pages 15-18"},"PeriodicalIF":0.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Boris Melloni (Professeur des universités, pneumologue), François Vincent (Professeur des universités, pneumologue)
{"title":"La nébulisation en pneumologie : médicaments, indications et bonnes pratiques","authors":"Boris Melloni (Professeur des universités, pneumologue), François Vincent (Professeur des universités, pneumologue)","doi":"10.1016/j.actpha.2025.04.007","DOIUrl":"10.1016/j.actpha.2025.04.007","url":null,"abstract":"<div><div>Les principaux médicaments utilisés en nébulisation sont les bronchodilatateurs, les corticoïdes et les antibiotiques. Ils permettent de traiter principalement l’asthme, la bronchopneumopathie chronique obstructive, la mucoviscidose et les bronchectasies ou dilatations des bronches. À l’officine, il convient de bien connaître les médicaments pouvant être nébulisés ainsi que les bonnes pratiques de nébulisation.</div></div><div><div>The main drugs used in nebulization are bronchodilators, corticoids and antibiotics. They are mainly used to treat asthma, chronic obstructive pulmonary disease, cystic fibrosis and bronchiectasis or bronchial dilatation. At the pharmacy, it’s important to know which drugs can be nebulized, and how best to use them.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 647","pages":"Pages 29-33"},"PeriodicalIF":0.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jacques Buxeraud (Professeur des universités) , Sébastien Faure (Professeur des universités)
{"title":"Le mavacamten (Camzyos®), un nouveau médicament en cardiologie","authors":"Jacques Buxeraud (Professeur des universités) , Sébastien Faure (Professeur des universités)","doi":"10.1016/j.actpha.2025.04.002","DOIUrl":"10.1016/j.actpha.2025.04.002","url":null,"abstract":"<div><div>Le mavacamten est un nouveau médicament destiné à traiter une pathologie cardiaque, la cardiomyopathie hypertrophique symptomatique. Il appartient à la classe des inhibiteurs de la myosine cardiaque.</div></div><div><div>Mavacamten is a new drug designed to treat symptomatic hypertrophic cardiomyopathy. It belongs to the class of cardiac myosin inhibitors.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 647","pages":"Pages 10-12"},"PeriodicalIF":0.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jean-Marie Vaugeois (Professeur de pharmacologie) , Sébastien Faure (Professeur des universités)
{"title":"Hypokaliémie induite par la caféine, un effet indésirable à ne pas négliger","authors":"Jean-Marie Vaugeois (Professeur de pharmacologie) , Sébastien Faure (Professeur des universités)","doi":"10.1016/j.actpha.2025.04.011","DOIUrl":"10.1016/j.actpha.2025.04.011","url":null,"abstract":"<div><div>La caféine est consommée quotidiennement par des millions de personnes dans le monde. Elle entre également dans la composition de médicaments. Une consommation journalière modérée, inférieure à 400 mg, est sans risque majeur pour la santé, sauf pour les femmes enceintes et les enfants. Une intoxication à la caféine peut entraîner une hypokaliémie sévère, dont le mécanisme n’est pas complètement élucidé, et mettre en jeu le pronostic vital. La prudence est de mise au comptoir face à un patient qui risque de présenter une kaliémie diminuée à cause de sa pathologie ou de la prise de médicaments hypokaliémiants, et qui consomme de la caféine.</div></div><div><div>Caffeine is consumed daily by millions of people worldwide. It is also an ingredient in medicines. A moderate daily caffeine intake of less than 400 mg is not a major health risk, except for pregnant women and children. However, caffeine intoxication can lead to severe hypokalemia, the mechanism of which is not yet fully understood, and can be life-threatening. Caution should be exercised at the counter when a patient’s pathology or hypokalemic drugs put them at risk of decreased kalemia, and he consumes caffeine.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 647","pages":"Pages 47-50"},"PeriodicalIF":0.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Le moustique tigre, une propagation synonyme de maladies vectorielles","authors":"Anne-Solène Naudon (Docteure en pharmacie)","doi":"10.1016/j.actpha.2025.03.014","DOIUrl":"10.1016/j.actpha.2025.03.014","url":null,"abstract":"<div><div>Originaire d’Asie du Sud-Est et observé pour la première fois en France en 2004 dans les Alpes-Maritimes, le moustique tigre s’est depuis propagé sur le territoire. Des mesures prophylactiques, individuelles ou collectives, sont mises en place pour limiter son expansion et la transmission des maladies dont il est le vecteur. Les équipes officinales peuvent s’impliquer dans la sensibilisation et la prévention de la dengue, du chikungunya et de la maladie à virus Zika.</div></div><div><div>Originally from Southeast Asia, the tiger mosquito was first observed in France in 2004 in the Alpes-Maritimes region, and has since spread across the country. Prophylactic measures, both individual and collective, are in place to limit its spread and the transmission of the diseases it carries. Pharmacy teams can get involved in raising awareness and preventing dengue fever, chikungunya and the Zika virus disease.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 646","pages":"Pages 53-56"},"PeriodicalIF":0.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Les cathinones de synthèse, une prévention indispensable dans les milieux à risque","authors":"Anne-Solène Naudon (Docteure en pharmacie)","doi":"10.1016/j.actpha.2025.03.009","DOIUrl":"10.1016/j.actpha.2025.03.009","url":null,"abstract":"<div><div>Bien que leur consommation reste marginale, les cathinones de synthèse circulent de plus en plus en France, notamment dans certains milieux. Apparues sur le marché des drogues dans les années 2000, ces substances ont pour origine les feuilles de khat, une plante ancestrale largement consommée dans les régions jouxtant la mer Rouge qui renferme des alcaloïdes naturels, dont la cathinone.</div></div><div><div>Although their use remains marginal, synthetic cathinones are increasingly circulating in France, particularly in certain circles. Introduced to the drug market in the 2000s, these substances originate from khat leaves, an ancestral plant widely consumed in regions bordering the Red Sea, which contains natural alkaloids, including cathinone.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 646","pages":"Pages 33-36"},"PeriodicalIF":0.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linda Amrouche (Titulaire d’un master 2 en pharmacologie préclinique et clinique)
{"title":"Opioïdes de synthèse, la course à la puissance","authors":"Linda Amrouche (Titulaire d’un master 2 en pharmacologie préclinique et clinique)","doi":"10.1016/j.actpha.2025.03.010","DOIUrl":"10.1016/j.actpha.2025.03.010","url":null,"abstract":"<div><div>Parmi les nouveaux produits de synthèse, les nitazènes et les fentanyloïdes peuvent provoquer des overdoses mortelles. Ces substances sont au centre d’un trafic de stupéfiants qui alimente une crise sanitaire particulièrement meurtrière, notamment aux États-Unis. Seules des actions synergiques pourront renforcer l’efficacité des stratégies de prévention, de sensibilisation et de coopération juridique nécessaires pour lutter contre cette véritable pandémie.</div></div><div><div>Among the new synthetic products, nitazenes and fentanyloids can cause fatal overdoses. These substances are at the heart of a drug trade that is fuelling a particularly deadly health crisis, particularly in the United States. Only synergetic action can boost the effectiveness of the prevention, awareness-raising and legal cooperation strategies needed to combat this veritable pandemic.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 646","pages":"Pages 37-39"},"PeriodicalIF":0.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}